Improving siRNA Production Efficiency
With engineered double-stranded RNA (dsRNA) ligases
Demand for oligonucleotide therapeutics, such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), has skyrocketed as their use has expanded to encompass larger disease indications. This exciting shift in the industry creates the need for enhanced manufacturing technologies.
In this paper, we showcase how engineered double-stranded RNA (dsRNA) ligases, designed for ligation of RNA fragments as a novel synthesis approach to improve siRNA production efficiency.
Engineered dsRNA ligases can efficiently scale siRNA manufacturing through:
- Faster process development
- Improved manufacturability
- Custom pharma manufacturing expertise
- Higher scalability
- Complements solid state synthesis
See how by downloading this white paper.